Complete Story


Moderna Says COVID Vaccine Has Fewer Breakthrough Cases than Pfizer’s

However, it does have a higher risk of myocarditis rates in young men

Moderna defended the use of its COVID-19 vaccine Thursday, saying the protection it offers against severe disease, hospitalization and death outweighs the risk of myocarditis, a rare heart condition seen in a small number of young men who received the shot.

The company announced last week that the Food and Drug Administration (FDA) needed more time to decide whether to authorize its two-dose vaccine for use in children ages 12 to 17 as the agency looks into reports of myocarditis, or the inflammation of the heart muscle.

Reported cases of the rare heart inflammation in men under age 30 are relatively higher after Moderna's vaccine compared with those who received the shots made by Pfizer and BioNTech, Moderna Chief Medical Officer Dr. Paul Burton told reporters on a call Thursday.

Please select this link to read the complete article from CNBC.

Printer-Friendly Version